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positively on prescribing behavior at Ussher Polyclinic with significant changes 
between the pre-intervention and post-intervention periods.  
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OBJECTIVES: The Pharmacy and Therapeutic Committee in the hospital planned 
to study the aggregate medicine use in the hospital. After implementation of the 
Essential Drug List (EDL) 2011, it was important to know the consumption and 
cost contributed by each pharmaceuticals in the list so that further revisions 
could be done on the list annually. METHODS: The study was conducted for one 
year using Always Better Control (ABC) analysis of pharmaceuticals in the EDL. 
Pharmaceuticals from the EDL were categorized for A (70%) B (20%) C (10%) 
categories. The calculations were done from a period of January 11, 2011 to 
January 11, 2012 using the data from the hospital billing database. RESULTS: The 
total annual drug expenditure (ADE) was Rs. 2,61,78,251. Out of 311 
pharmaceuticals in the list, 47 (15%) were in A group, 60 (19%) were in B group 
and the remaining 204 (66%) were in C group. In the A group 45% of the 
pharmaceuticals were belong to ATC category J (Antimicrobials). Out of the top 
10 pharmaceuticals, the costlier one was Anti D Immunoglobulin costing Rs. 
1995. But it came on sixth position as the consumption was lesser than the other 
ones in the top. The first one was Lopinavir-Ritonavir combination with an 
annual cost of 13, 76529. Insulin was on fourth position with an annual 
expenditure just short of one million Indian Rupees. The top 10 include 3 anti-
virals and 2 anti-bacterial preparations showing the high consumption and costs 
of the anti-microbial agents. The least unit cost in the A category was Rs. 0.18 for 
ferrous sulphate – folic acid combination. CONCLUSIONS: Antimicrobilas 
consumed major resources of the charity hospital. Control on antimicrobial 
prescription with updated protocols and adoption of government free supply of 
anti-retroviral drugs will substantially reduce the hospital budget on medicines.  
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OBJECTIVES: Uninsurance has been shown to reduce health care utilization, but 
this effect may vary by uninsurance duration. Moreover, some argue that 
attitudes toward health insurance and medical care confound the association 
between uninsurance and utilization, but are rarely examined because they are 
often unobserved. This study examined the effects of uninsurance duration on 
prescription medication (RX) and emergency department (ED) utilization after 
adjusting for individuals’ attitudes towards health care and health insurance in 
US nonelderly adults. METHODS: Pooled data from panels 9 to 14 of the MEPS 
longitudinal data files (2004-2010) were used. Uninsured individuals were 
categorized by duration of uninsurance as 1-5, 6-11, 12-23 months and >=2 years 
and were compared to two-year privately and two-year publicly insured 
individuals. Four attitudinal responses were explored, including 
acknowledgement that one is more likely to take risks than the average person 
and beliefs that one is too healthy to need insurance, that insurance is not worth 
the cost, and that one is able to overcome illness without professional help. 
Zero-inflated Poisson and zero-inflated negative binomial models were applied 
using complex survey design correction in STATA 12 to adjust for differences in 
sociodemographic characteristics and health status. Results were reported as 
incidence rate ratios with 95% confidence intervals. RESULTS: Compared to two-
year privately insured, individuals who were uninsured >=6 months used fewer 
RXs, and the reduction increased with uninsurance duration. All uninsured 
categories had more ED visits compared to two-year privately insured with no 
clear trend by duration. Including attitudinal variables had negligible effect on 
estimates of uninsurance. Those disagreeing with the attitudinal responses were 
found to utilize more RX; only those who disagreed with being able to overcome 
illness without help were found to have increased ED utilization. CONCLUSIONS: 
Uninsured had fewer prescription drugs but more ED visits. Attitudes towards 
insurance and medical care did not confound uninsurance effect.  
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OBJECTIVES: To determine the nature and types of medication prescribing errors 
in Egyptian community setting. METHODS: The preparation of this study 
involved a survey of 800 medical prescriptions of different specialties collected 
from outpatients in Egyptian community setting and analyzed to determine the 
nature and types of medication prescribing errors. RESULTS: Out of the 2241 
errors observed, the lack of diagnosis and patient information were noted in 
17.89% and 14.77% respectively making them the top most medication error. This 
was followed by drug-drug interactions (DDIs) were noted in 13.97% of 
prescription, illegible handwriting in 8.66%, lack of signature in 7.89%, treatment 
duration not mentioned in 7.05%, unspecified allergy in 5.44%, inappropriate 
dose in 3.75%, drug without dose in 3.44%, use of abbreviations in 3.03%, 
inappropriate/lack of indication in 2.85%, drugs without administration route in 
2.81%, drugs with the same indication in 2.78%, dose higher than recommended 
in 2.10%, wrong frequency in 1.23%, drugs with wrong/inappropriate route in 
1.22%, confusion with drug name in 0.76%, and inappropriate use of decimal 
points in 0.22% of prescriptions. CONCLUSIONS: 1) Most prescriptions 
investigated were inadequate in terms of legibility, use of abbreviations and 
omitted items, entailing serious risks for patient safety; 2) All prescribing errors 
occurred are preventable; and 3) Electronic prescriptions, computerized 
physician order entry (CPOE), software assisted clinical decision may also 
significantly reduce prescribing errors.  
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OBJECTIVES: Injectable medications are common in the hospital setting and 
susceptible to errors that may harm patients. We conducted a descriptive analysis 
of injectable medication errors reported in the hospital setting in order to inform 
prevention efforts. METHODS: Year 2011 records documenting medication errors 
associated with injectable drugs were extracted from a national medication error 
reporting system representing ~1000 United States hospitals (Quantros Medmarx). 
Injectable medications were defined by administration routes “subcutaneous”, 
“intravenous”, “intramuscular”, or “epidural”. Records identifying inpatient and 
outpatient errors that reached the patient (National Coordinating Council 
Medication Error Reporting and Prevention Categories C-I) were analyzed. For each 
record, staff type (discovered error), physical location, stage within the medication 
use process (prescribing, transcribing, dispensing, administering, monitoring, 
procuring) and error type were analyzed. RESULTS: 5389 records identified 
injectable medication errors (4860 inpatient, 529 outpatient). Although seventeen 
different staff types discovered errors, 75% of records identified a nurse as 
discovering the error. Error locations most frequently reported were nursing units 
(59%), pharmacy (16%), ICU (10%), and emergency department (8%). The distribution 
of errors throughout the medication use process was: administering (57%), 
dispensing (20%), transcribing (12%), prescribing (8%), monitoring (2%) and 
procuring (1%). During administering, errors were most often typed as “omission 
error” (34%), “improper dose/quantity” (20%), “unauthorized/wrong drug” (10%), 
“wrong time” (9%), “wrong administration technique” (9%) and “extra dose” (8%). 
During dispensing (includes pharmacy preparation), errors were most often typed 
as “omission error” (25%), “improper dose/quantity” (20%), “wrong time” (17%) and 
“unauthorized/wrong drug” (10%). CONCLUSIONS: In 2011, the most frequent 
injectable medication errors were related to drug administering in nursing units 
and dose preparation and timing in pharmacy dispensing, with dose accuracy being 
a contributing factor in both locations. Prevention efforts can be targeted on 
medication use processes and hospital locations where errors occur most often.  
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OBJECTIVES: The objective of this study is to project the number of nonelderly 
people who could gain coverage under the Patient Protection and Affordable Care 
Act (PPACA) for the period from 2014 through 2020 in the 13-county Houston-
Galveston area region. METHODS: The 2008 and 2009 American Community 
Survey (ACS) Public Use Microdata file data were used to obtain current county-
level data on the uninsurance rate in the region, weighted by age, income, and 
citizenship status. The impact of PPACA was projected based on estimates of 
growth in the size of targeted populations in each county and the anticipated 
responses of those populations to the major provisions of PPACA. To project 
coverage with PPACA, participation rates (the percent of the eligible population 
likely to enroll in Medicaid or purchase private insurance in an exchange or 
elsewhere) were applied to the projected number of uninsured in applicable 
groups. The participation rates are informed assumptions based on the best 
evidence available from public and private insurance studies currently available 
in the literature. RESULTS: We estimated county level projection in the 12-
county Houston-Galveston region. The projections indicate that, if fully 
implemented, PPACA could cut the uninsurance rate in the region by half, from 
26% in 2010 to 13% in 2020. This change translates into health insurance 
coverage for approximately 2 million additional people, from the current 4.2 
million to a projected 5.9 million. The number of Medicaid enrollees could 
increase by an estimated 600,000 (a 79% increase), although private insurance 
coverage, which could increase by as much as 1 million enrollees (a 30% 
increase), will remain the primary source of coverage for most people. 
CONCLUSIONS: Coverage gains from PPACA will vary considerably by county, 
depending on the age-income-citizenship characteristics of the population, 
current uninsurance rates, and the rate of population growth.  
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SUCCESSFUL RECRUITMENT STRATEGIES FOR WOMEN PARTICIPATION IN 
HEALTH RESEARCH STUDIES: A META-ANALYSIS  
Bansal D, Gudala K, Shah C, Chavda M 
National Institute of Pharmaceutical Education and Research, Mohali, India  
OBJECTIVES: To evaluate and synthesize the evidence regarding effective and 
efficient interventions to enhance enrollment of women into health research 
study. METHODS: Comprehensive search done in PubMed, EBSCO, and ProQuest 
databases looking for studies evaluating different recruitment interventions (RI) 
for women participation in clinical trials/observational studies. Studies were 
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excluded if their target population did not specifically focus on women 
recruitment. We estimated the frequency of RI with which women were 
recruited by pooling across studies that presented data for RI used to enhance 
participation in HRS as proportions and 95% confidence intervals (CIs) for each RI 
using random-effects model. STATA (version 11.0) was used to perform the 
analysis. RESULTS: We analyzed 15 interventional studies (n=9266) and 5 
observational studies (n=2536). RI were classified into four categories; Referral, 
Social marketing (SM), health system (HS) and community outreach (CO). SM 
used in 96%, referrals 77%, CO in 50% and HS 88% studies. In aggregate, SM lead 
to 63.9%(63-64.7), referrals 14.5% (13-15.2), CO 20%(19-22), and HS 13.6% (13-14.7) 
participant recruitment. SM was the most effective RI in 69% (14 of 20) of studies 
it was attempted. CONCLUSIONS: This study found that social marketing as 
most effective strategy in the studies it attempted compared to other 
intervention.The identification of such RI to enhance participation in HRS should 
help researchers to develop strategies that will keep to a maximum participation 
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OBJECTIVES: In 2012 CONITEC (Brazilian National Commission of HTA) rules, 
information checklist and timelines, were officially established for medicines, 
procedures and devices. One year after the start of this new process, 132 
processes were submitted to the commission. The objective of this research is to 
present a quantitative and qualitative analysis of this process. METHODS: 
Analysis of the CONITEC different reports until Dec 31 2012 in relation to the 
established public health care programs and the 2012-2015 Brazilian national 
health plan. RESULTS: Of the 132 submitted processes, 98 were analyzed until 
Dec 31 2012. 40 submissions were recused by non-conformity with the 
documentation checklist; 35 had a positive answer for inclusion in the public 
health care reimbursement system and of them 24 were submitted by the 
government itself, 10 by both the government and manufacturers and 1 by the 
manufacturer alone; 23 did not achieve a positive recommendation; 34 
submissions are still under evaluation. Technologies that were incorporated 
have a public health care program. Inclusion occurred because the technology 
was considered to have enough clinical evidence, represent savings for the 
system or was considered effective and although not representing savings to the 
system the government considered it an investment in a strategic disease. The 
main reasons for not achieving a positive recommendation for inclusion were: 
insufficient clinical data, inadequate economic studies to the local scenario, 
negative evaluations from other commissions (NICE and Scottish medicines 
consortium, mainly) and inexistence of real world public data. CONCLUSIONS: 
Considering these results, a well-established clinical data program, stakeholders 
mapping, understanding of the local needs and scenario, careful analysis of the 
implications for the system of the technology inclusion and a very well planed 
market access strategy are mandatory before submitting new health technology 
to the evaluation commission, which is the end process of a negotiation.  
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OBJECTIVES: In order to improve the medication access for the Brazilian citizens, 
the CAP (Price Coefficient), which is the mandatory minimum discount, was 
regularized by the Brazilian Chamber of Pharmaceutical Market Regulation in 
December 2006. This discount must be used not only on the prices of high cost 
drugs, when they are purchased by the government, but also on every 
medication which are obtained by judicial process. The objective of this study is 
to present a case study which evaluates the fulfillment of CAP on the acquisition 
by judicial process of a medication indicated to treat a rare disease. METHODS: 
Economic information (number of units sold and total sales from governmental 
acquirements per month, number of patients treated by the new drug) between 
December 2010 and November 2012 were provided by the pharmaceutical 
industry from two different via. One of them is the mandatory annual report of 
commercialization, which is an instrument to monitor the Brazilian 
pharmaceutical market. The other information source is the requirement, which 
was made when the entry price was established for that specific technology. 
RESULTS: During the period of the study, all the medications were bought 
through the judicial process by the SUS (Brazilian Public Health System) and the 
CAP was properly used; the sale price practiced was much close to the maximum 
government sale price. However, there are differences between the information: 
the number of patients, the number of units sold and the total sales. 
CONCLUSIONS: Especially in cases of medications with high treatment cost, it is 
very important to assess the use of the CAP discount by different way of 
requirement, not only by the annual commercialization report. The CAP discount 
allowed improving the medication access by SUS with lowest price, more than 
20% of the discount on the maximum fabric price.  
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OBJECTIVES: Resolution nº 2/2004 dictates the criteria to establish the entry 
prices of new medicines in Brazil. According to it, products are divided into: new 
products and new presentations. This research will focus in new products, which 
are classified in: Category I - new product (patented molecule) with scientific 
evidences of benefit when compared to others of same therapeutic indication 
(greater efficacy; same efficacy with decreased side effects or same efficacy with 
lower global cost). Category II - new products not classified as I. Price analysis 
follows a model of price cap, including two constraints: lowest international 
price (based on a list of nine countries plus where the product is produced) and 
cost of treatment, based on an elected comparator. Price for Category I is based 
on the lowest international price only and, for Category II, the cost of treatment 
with the chosen comparator and international prices, the lowest of them. The 
goal of this research is to evaluate the application of price regulation since 
Resolution nº 2/2004 publication and its consequences regarding to decreasing 
the costs of medicines for the society. METHODS: Data of price analysis (new 
products) performed by Office of Economic Assessment of New Technologies of 
Brazilian Health Surveillance Agency (Anvisa), which supports CMED decisions, 
were evaluated (2004–2011). RESULTS: In * years, 209 new molecules (563 
presentations) were analyzed. The mean difference found between the price 
pleaded by laboratories and the price determined after analysis was: Category I 
21%; Category II 39%. Only 7% of new products proved to be innovative, while 
93% of the new products were classified as II (either not under patent or without 
proven benefit). CONCLUSIONS: Resolution n° 2/2004 has led to lower entry 
prices and, consequently, decreased the cost to the private and public sector, 
improving the efficiency of health care.  
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OBJECTIVES: Previous research demonstrated that prices do not vary across 
countries based on macroeconomic variables. We present a framework 
comparing profits under differential pricing with homogenous pricing. 
METHODS: We developed a model based on monopolistic pricing theory to solve 
for a static efficiency solution. The demand curve for a given market, i, is Q=ai-
biP, where Q is quantity and P is price. For a given market, factors that could 
influence the shape of our demand curve (parameters ai and bi) include 
purchasing power, burden of disease, drug access in other markets, 
completeness of the health system, income and wealth equality, ease of market 
access, and market stability. Given these factors, we show a theoretic solution 
for 2 markets (one “rich” and one “poor”) and compare the profits under our 
model versus a single global price system. We assume the “rich” market (lower 
price elasticity) and “poor” (higher price elasticity) market have demand curves 
Q=2-0.1P and Q=2-0.5P, respectively. RESULTS: For i=1,2, the profit, π, from a 
single price is π=PQ-cQ=P(a1-b1P+a2-b2P)-c(a1-b1P+a2-b2P). The optimal price is then 
P=(a1+a2+c(b1+b2))/(2(b1+b2)). If the monopolistic firm does indeed price 
discriminate, the optimal price for market i would be Pi=(ai+cbi)/(2bi). Our findings 
indicate that the potential profit between a single price scenario and a price 
discriminating scenario increases as the elasticities bi vary. In our two market 
example, the single price (SP) model has a profit πSP=4.82 compared with a price 
discriminant (PD) model of profit πPD=10.15. Not only is πPD over twice the size of 
πSP, but in some cases the total output also increases, which results in welfare 
gain. CONCLUSIONS: The optimal pricing solution for pricing pharmaceuticals 
around the world implies prices should vary based on economic factors. This is 
not currently observed in practice, which results in lost rents.  
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OBJECTIVES: Economic analysis has traditionally been utilized in health care 
decision making when applied to high-cost medical technologies. However, 
health care decision making in the United States (US) seldom considers ethical 
principles such as distributive justice. There tends to be an inherent conflict 
between cost-effectiveness and patient’s interest. How these conflicts are 
resolved, needs to be informed by both economic and ethical analysis. The study 
objective is to assess the extent to which ethical principles are utilized along 
with economic analysis in health care decision-making. METHODS: A systematic 
literature search was conducted among peer-reviewed journals in electronic 
databases such as Scopus and EconLit. No time-frame was stipulated for these 
searches and inclusion was not limited to the language or the country where the 
study was conducted. RESULTS: A total of 81 articles were identified and 17 
studies were reviewed based on the inclusion/exclusion criteria. The review 
supported an integration of evidence, economics and ethics in health technology 
assessment (HTA). Some ethical perspectives discussed in the HTA included: 
decisions should be accountable to democratic procedure and citizen 
participation; balance between utility and fairness; and inherent conflict 
between provider fiduciary responsibility to patients and cost effectiveness. 
Developing criteria for allocation of high-cost medical technology was the most 
discussed issue. A survey of health professionals from Western Europe 
documented that 90% believed ethical analysis was important in HTA but was 
constrained by practical issues. CONCLUSIONS: The incorporation of ethical 
perspectives into health care decision-making is still in its infancy. No efforts 
